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Introduction: Optimal preoperative treatment of stage IIB/III NSCLC 
is yet unknown and a subject of controversy. Induction chemotherapy 
(CT) yields a pathologic response (pCR) rate ranging from 8 to 19% 
and a mediastinal down-staging rate ranging from 45 to 60%. Ac-
cording to results of the INT0139 trial (Albain KS et al, Proc ASCO 
2005, abstr#7014) and recent published data (Kwong KF et al, JTCS 
2005;129:1250-7) induction chemo-radiotherapy (CRT) seems superior 
in terms of pCR (18-40.5%). Our goal is to conﬁrm pCR and analyse 
survival after CRT in our community-based treatment center. 
Patients et method: Patients (pts) were selected in a multidisciplinary 
committee according to functional and resecability criteria. Induc-
tion treatment comprised 45 Gy RT delivered to primary tumor and 
pathologic hilar and/or mediastinal nodes on CT-can (CTV) with an 
extra-margin of 1 to 1.5 cm (PTV). A 5-ﬁeld technique was used for all 
patients with 8-25 MV photons. Concurrent CT regimen was CDDP 20 
mg/m2 d1-d5 and Etoposide 50 mg/m2 d1-d5 (PE), d1-5 d29-33; 3 to 
4 weeks after CRT completion, operability was re-assessed according 
to PS and a CT-scan. Surgery was performed 1 to 2 weeks later in pts 
deemed resectable. Inoperable pts were referred for a 20 Gy boost ± 1 
extra-cycle of PE.
Results: from 1996 to 2005, 107 pts (91H/16F, median age: 59 yrs. 
[31-81], OMS 0-1: 94.4%) were initially selected and received CRT 
(stage IIB(Pancoast) 18, IIIA 58 and IIIB 31, SCC 48%, Adeno.44%, 
Large c.14%). 2 pts stopped treatment prematurely (sudden death 1, 
refusal 1), 100 pts received 45 Gy and 2 cycles de PE concurrently 
(fatigue 3, renal failure 1, unknown reason 1), 72 pts had a thora-
cotomy after preop evaluation (pneumonectomy 21, lobectomy 45, 
bi-lobectomy 5, exploratory only 1). During the 3-months postop time, 
5 pts (6.9%) died, 4 after pneumonectomy (R 3, L 1). The analysis of 
tumoral samples showed a pCR (or microscopic residual foci) rate of 
39.5% in 71 cTany Nany pts and a sterilized mediastinal nodes rate of 
60.9% in 46 cTanyN2 pts. Median (med) follow-up time of survivors 
was 36.8 months (mo.), 2yrs. and 3yrs.-OS was 55 et 40% respec-
tively (med=26.7 mo.) for all the ITT population (n=107), 62 et 51% 
(med=36,5 mo.) for 71 resected, 41 and 16% for the 36 non-resected 
pts (med=19,1 mo.). On multivariate analysis, surgical resection and 
tumoral necrosis > 50% (or pCR) were the most pertinent predic-
tive factors of the risk of death (HR=.50 and .48, p=.006 and .038 
respectively). Stage (IIB vs IIIA/B) had no signiﬁcant inﬂuence on OS 
(HR=1.39, p=0.36) in our series.
Conclusion: Surgery is feasible after induction CRT, particularly (bi-
)lobectomy, in PS 0-1 stage IIB(Pancoast)/III NSCLC pts but pneumo-
nectomy should not be performed even if necessary (particularly, right 
pneumonectomy). Pathological response to induction chemo-RT was 
high and is a major predictive factor of OS (necrosis > 50 % or pCR). 
Survival of resected patients was encouraging. A randomized trial is 
needed to determine whether induction CRT is superior to CT alone.
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Risk of central nervous system bleeding in patients with brain 
metastases from non-small cell lung cancer (NSCLC) following 
whole brain radiation therapy (wbrt) is low
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Background: The risk of central nervous system (CNS) bleeding in 
patients with brain metastases from NSCLC is not well known. With 
increasing use of bevacizumab, the risk of CNS hemorrhage may in-
crease. The purpose of this study was to assess the risk for CNS hemor-
rhage in NSCLC patients with one or more brain metastases enrolled in 
two large randomized trials of WBRT± Motexaﬁn gadolinium (MGd). 
Methods: In protocol 9801, 401 pts with brain metastases from any 
primary tumor were randomized to WBRT (30 Gy/10 fractions) or 
WBRT+MGd, 5 mg/kg qd x 10 days. The subgroup of 251 pts with 
NSCLC is included in this analysis. In protocol 0211, 554 pts with 
brain metastases from NSCLC were randomized to the same treat-
ments. In both studies, eligibility included a KPS ≥ 70, no liver metas-
tases, and ≤1 site of extracranial metastasis. In both studies, a primary 
endpoint was time to neurologic progression. Patients were followed 
for adverse events for one month, and for serious adverse events for 
6 months following randomization. The adverse event database was 
queried for CNS hemorrhage terms.
Results: 805 patients, with a median age of 59 years, 44.6% female, 
55.4% male, 53.3% adenocarcinoma, 19.3% NSCLC, not other-
wise speciﬁed (NOS), 13.4% squamous cell, 10.6% large cell, 0.9% 
bronchoalveolar, 19.7% single brain metastasis, 80.3% multiple 
brain metastases, 47% extracranial metastases, and 84% presenta-
tion with neurologic deﬁcits were randomized to WBRT (N=403) or 
WBRT+MGd (N=402). 12 Patients (1.5%) developed CNS bleeding: 5 
(41.7%) adenocarcinomas, 3 (25%) large cell, 2 (16.7%) each squa-
mous cell and NSCLC, NOS on average 144 days after brain metas-
tasis diagnosis (median 85 days, range 24-379 days). Patients who 
developed CNS hemorrhage presented earlier with brain metastases in 
their course of lung cancer (median of 4.1 weeks from diagnosis of the 
primary cancer to treatment of brain metastases), than those who did 
not (median 12.9 weeks). Otherwise, the characteristics of patients who 
developed CNS hemorrhage reﬂect the remainder of the population. 
The median survival of patients with CNS hemorrhage was 4.2 months 
from randomization, compared with 5.1 months for the remaining 
patients (P=0.196).
Conclusions: CNS hemorrhage is an infrequent complication of pa-
tients with brain metastases who undergo WBRT. Patients who develop 
brain metastases earlier in their disease are at greater risk.
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An audit of elective mediastinal lymph node irradiation in stage 
III non-small cell lung cancer patients entered onto a prospective 
randomized phase III study
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Background: The standard radical radiation treatment volumes used 
in Stage III non-small cell lung cancer (NSCLC) have traditionally 
